Skip to main content
SpringerLink
Log in

Pharmaceutical Management of Ovarian Cancer

Current Status

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Over recent decades, truly impressive progress has been made in the outcome associated with the pharmacological antineoplastic management of women with advanced ovarian cancer. Following initial surgery, the large majority of patients with this malignancy will receive a chemotherapy regimen that includes a platinum drug (carboplatin or cisplatin) and a taxane (paclitaxel or docetaxel). Currently, objective responses are observed in approximately 60–80% of patients treated in the front-line setting, with documented improvements in overall survival compared with prior non-platinum and taxane programmes. Unfortunately, despite the high response rate to initial chemotherapy, the majority of women with advanced disease will experience recurrence of the malignant process and be candidates for a variety of possible second-line therapeutic options. It is well recognized that ovarian cancer patients who are documented to experience an initial response to platinum-based chemotherapy but where the disease recurs approximately 6 or more months following the completion of primary therapy, may have another clinically meaningful response (both objective and subjective) to a second platinum-based strategy. However, an optimal management approach in this setting remains to be defined. Furthermore, the malignant cell populations in all ovarian cancer patients who experience an initial relapse of the disease process will eventually be resistant to the platinum agents. In this setting, multiple drugs have been shown to be biologically active. Again, an optimal strategy to be employed in the platinum-resistant setting has yet to be demonstrated through the conduct of evidence-based trials. Reasonable goals of therapy in women with recurrent or resistant ovarian cancer are to improve overall survival, reduce the severity (and delay the occurrence) of symptoms and optimize overall quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Bateman JC. Chemotherapeutic management of advanced ovarian carcinoma. Med Ann Dist Columbia 1959; 28: 537–44

    PubMed  CAS  Google Scholar 

  2. Kottmeier HL. Treatment of ovarian cancer with thiotepa. Clin Obstet Gynecol 1968; 11(2): 428–38

    PubMed  CAS  Google Scholar 

  3. Thigpen T, Vance R, Lambuth B, et al. Chemotherapy for advanced or recurrent gynecologic cancer. Cancer 1987; 60 (8 Suppl.): 2104–6

    Article  PubMed  CAS  Google Scholar 

  4. Greene MH, Boice Jr JD, Greer BE, et al. Acute nonlympho-cytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med 1982; 307(23): 1416–21

    Article  PubMed  CAS  Google Scholar 

  5. Travis LB, Curtis RE, Boice Jr JD. Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Res 1996; 56: 1564–70

    PubMed  CAS  Google Scholar 

  6. Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999; 340: 351–7

    Article  PubMed  CAS  Google Scholar 

  7. Katz ME, Schwartz PE, Kapp DS, et al. Epithelial carcinoma of the ovary: current strategies. Ann Intern Med 1981; 95(1): 98–111

    PubMed  CAS  Google Scholar 

  8. Young RC, Chabner BA, Hubbard SP, et al. Advanced ovarian adenocarcinoma: a prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 1978; 299(23): 1261–6

    Article  PubMed  CAS  Google Scholar 

  9. Omura GA, Morrow CP, Blessing JA, et al. A randomized comparison of melphalan versus melphalan plus hex-amethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 1983; 51(5): 783–9

    Article  PubMed  CAS  Google Scholar 

  10. Talley RW, O’Bryan RM, Gutterman JU, et al. Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875): phase I clinical study. Cancer Chemother Rep 1973; 57(4): 465–71

    PubMed  CAS  Google Scholar 

  11. Rozencweig M, Von Hoff DD, Slavik M, et al. Cis-diam-minedichloroplatinum (II): a new anticancer drug. Ann Intern Med 1977; 86(6): 803–12

    PubMed  CAS  Google Scholar 

  12. Von Hoff DD, Schilsky R, Reichert CM, et al. Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep 1979; 63(9–10): 1527–31

    Google Scholar 

  13. Loehrer PJ, Einhorn LH. Drugs five years later: cisplatin. Ann Intern Med 1984; 100(5): 704–13

    PubMed  CAS  Google Scholar 

  14. Higby DJ, Wallace HJ, Albert DJ, et al. Diaminodichloropla-tinum: a phase I study showing responses in testicular and other tumors. Cancer 1974; 33: 1219–25

    Article  PubMed  CAS  Google Scholar 

  15. Wiltshaw E, Subramarian S, Alexopoulos S, et al. Cancer of the ovary: a summary of experience with cis-dichlorodiammineplatinum (II) at the Royal Marsden Hospital. Cancer Treat Rep 1979; 63: 1545–8

    PubMed  CAS  Google Scholar 

  16. Bruckner HW, Cohen CJ, Feuer E, et al. Prognostic factors: cisplatin regimens for patients with ovarian cancer after failure of chemotherapy. Obstet Gynecol 1987; 69: 114–20

    PubMed  CAS  Google Scholar 

  17. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987; 5(8): 1157–68

    PubMed  CAS  Google Scholar 

  18. Markman M. Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin N Am 2003; 17: 957–68

    Article  Google Scholar 

  19. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists Group. Br J Cancer 1998; 78(11): 1479–87

    Article  Google Scholar 

  20. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. BMJ 1991; 303: 884–93

    Article  Google Scholar 

  21. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and pacli-taxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000; 18(1): 106–15

    PubMed  CAS  Google Scholar 

  22. Omura GA, Bundy BN, Berek JS, et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1989; 7: 457–65

    PubMed  CAS  Google Scholar 

  23. GICOG. Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer. Gynecol Oncol 1992; 45: 115–7

    Article  Google Scholar 

  24. Conte PF, Bruzzone M, Chiara S, et al. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol 1986; 4: 965–971

    PubMed  CAS  Google Scholar 

  25. Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 1991; 9: 1668–74

    Google Scholar 

  26. A’Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13(3): 726–32

    PubMed  Google Scholar 

  27. Fanning J, Bennett TZ, Hilgers RD. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 1992; 80(6): 954–60

    PubMed  CAS  Google Scholar 

  28. The ICON Collaborators. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet 1998; 352: 1571–6

    Article  Google Scholar 

  29. Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992; 10(5): 706–17

    PubMed  CAS  Google Scholar 

  30. Swenerton K, Jeffrey J, Stuart G, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992; 10(5): 718–26

    PubMed  CAS  Google Scholar 

  31. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21(17): 3194–200

    Article  PubMed  CAS  Google Scholar 

  32. duBois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95(17): 1320–9

    Article  CAS  Google Scholar 

  33. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084–92

    PubMed  CAS  Google Scholar 

  34. Covens A, Carey M, Bryson P, et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002; 85(1): 71–80

    Article  PubMed  CAS  Google Scholar 

  35. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111(4): 273–9

    PubMed  CAS  Google Scholar 

  36. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994; 12(9): 1748–53

    PubMed  CAS  Google Scholar 

  37. Trimble EL, Adams JD, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11: 2405–10

    PubMed  CAS  Google Scholar 

  38. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332(15): 1004–14

    Article  PubMed  CAS  Google Scholar 

  39. Kris MG, O’Connell JP, Gralla RJ, et al. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 1986; 70: 605–7

    PubMed  CAS  Google Scholar 

  40. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334(1): 1–6

    Article  PubMed  CAS  Google Scholar 

  41. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl J Inst 2000; 92: 699–708

    Article  CAS  Google Scholar 

  42. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360: 505–15

    Article  Google Scholar 

  43. Connelly E, Markman M, Kennedy A, et al. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol 1996; 62(2): 166–8

    Article  PubMed  CAS  Google Scholar 

  44. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96(22): 1682–91

    Article  PubMed  CAS  Google Scholar 

  45. Lambert HE, Rustin GJ, Gregory WM, et al. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma: a North Thames Ovary Group Study. Ann Oncol 1997; 8(4): 327–33

    Article  PubMed  CAS  Google Scholar 

  46. Bertelsen K, Jakobsen A, Stroyer J, et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 1993; 49(1): 30–6

    Article  PubMed  CAS  Google Scholar 

  47. Hakes TB, Chalas E, Hoskins WJ, et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxo-rubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992; 45(3): 284–9

    Article  PubMed  CAS  Google Scholar 

  48. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995; 13(7): 1589–99

    PubMed  CAS  Google Scholar 

  49. Gore M, Mainwaring P, A’Hern R, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 1998; 16(7): 2426–34

    CAS  Google Scholar 

  50. Jakobsen A, Bertelsen K, Andersen JE, et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 1997; 15(1): 193–8

    PubMed  CAS  Google Scholar 

  51. Repetto L, Pace M, Mammoliti S, et al. The impact of received dose intensity on the outcome of advanced ovarian cancer. Eur J Cancer 1993; 29A(2): 181–4

    Article  PubMed  CAS  Google Scholar 

  52. Wrigley E, Weaver A, Jayson G, et al. A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals. Ann Oncol 1996; 7(7): 705–11

    Article  PubMed  CAS  Google Scholar 

  53. Conte PF, Bruzzone M, Carnino F, et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 1996; 14(2): 351–6

    PubMed  CAS  Google Scholar 

  54. Mobus V, Wandt H, Frickhofen N, et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: Intergroup trial of the AGO-Ovar-AIO and EBMT. J Clin Oncol 2007; 25: 4187–93

    Article  PubMed  CAS  Google Scholar 

  55. Grenman S, Wiklund T, Jalkanen J, et al. A randomized phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study. Eur J Cancer 2006; 42: 2196–9

    Article  PubMed  CAS  Google Scholar 

  56. Schilder RL, Brady MF, Spriggs D, et al. Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2003; 88: 3–8

    Article  PubMed  CAS  Google Scholar 

  57. Spriggs DR, Brady MF, Vaccarello L, et al. Phase III randomized trial of intravenous cisplatin plus a 24-or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007; 25: 4466–71

    Article  PubMed  CAS  Google Scholar 

  58. Bookman M, for the Gynecologic Cancer Intergroup. GOG 182-ICON 5: 5-arm phase III randomized trial of paclitaxel and carboplatin versus combinations with gemcitabine, pegylated liposomal doxorubicin or topotecan in patients with advanced-stage epithelial ovarian or primary peritoneal carcinoma [abstract no. 5002]. J Clin Oncol 2006; 24 (18S): 256s

    Google Scholar 

  59. duBois A, Weber B, Rochon J, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. J Clin Oncol 2006; 24: 1127–35

    Article  CAS  Google Scholar 

  60. De Placido S, Scambia G, Di Vagno G, et al. Topotecan compared with no therapy after response to surgery and carboplatin in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 2004; 22: 2635–42

    Article  PubMed  CAS  Google Scholar 

  61. Pfisterer J, Weber B, Reuss A, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006; 98: 1036–45

    Article  PubMed  CAS  Google Scholar 

  62. Hess V, A’Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004; 22(6): 1040–4

    Article  PubMed  CAS  Google Scholar 

  63. Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2005; 97(2): 436–41

    Article  PubMed  Google Scholar 

  64. Goff BA, Sainz de la CR, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60(3): 412–7

    Article  PubMed  CAS  Google Scholar 

  65. Crotzer DR, Sun CC, Coleman RL, et al. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 2007; 105(2): 404–8

    Article  PubMed  Google Scholar 

  66. Bergman F. Carcinoma of the ovary: a clinicopathological study of 86 autopsied cases with special reference to mode of spread. Acta Obstet Gynecol Scand 1966; 45: 211–31

    Article  PubMed  CAS  Google Scholar 

  67. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA 1955; 159: 1704–7

    Article  CAS  Google Scholar 

  68. Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62: 1–9

    PubMed  CAS  Google Scholar 

  69. Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 1985; 12: 1–6

    PubMed  CAS  Google Scholar 

  70. Markman M. Intraperitoneal chemotherapy. Crit Rev Oncol Hematol 1999; 31(3): 239–46

    Article  PubMed  CAS  Google Scholar 

  71. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2003; 4(5): 277–83

    Article  PubMed  CAS  Google Scholar 

  72. Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin-based chemotherapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991; 9: 1801–5

    PubMed  CAS  Google Scholar 

  73. Howell SB, Zimm S, Markman M, et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987; 5: 1607–12

    PubMed  CAS  Google Scholar 

  74. Recio FO, Piver MS, Hempling RE, et al. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer. Gynecol Oncol 1998; 68: 267–73

    Article  PubMed  CAS  Google Scholar 

  75. Markman M, Reichman B, Hakes T, et al. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol 1992; 10: 1479–84

    PubMed  CAS  Google Scholar 

  76. Barakat RR, Sabbatini P, Bhaskaran D, et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol 2002; 20: 694–8

    Article  PubMed  Google Scholar 

  77. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335(26): 1950–5

    Article  PubMed  CAS  Google Scholar 

  78. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19(4): 1001–7

    PubMed  CAS  Google Scholar 

  79. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354(1): 34–43

    Article  PubMed  CAS  Google Scholar 

  80. Elit L, Oliver TK, Covens A, et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 2007; 109(4): 692–702

    Article  PubMed  CAS  Google Scholar 

  81. Hess LM, Ham-Hutchins M, Herzog TJ, et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol 2007; 17: 561–70

    Article  CAS  Google Scholar 

  82. Trimble EL, Alvarez RD. Intraperitoneal chemotherapy and the NCI clinical announcement. Gynecol Oncol 2006; 103 (2 Suppl. 1): S18-9

    Google Scholar 

  83. Fung-Kee-Fung M, Provencher D, Rosen B, et al. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care. Gynecol Oncol 2007; 105(3): 747–56

    Article  PubMed  CAS  Google Scholar 

  84. Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 2006; 24(6): 988–94

    Article  PubMed  CAS  Google Scholar 

  85. Fujiwara K, Markman M, Morgan M, et al. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol 2005; 97: 10–5

    Article  PubMed  CAS  Google Scholar 

  86. Markman M, Hakes T, Barakat R, et al. Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. J Clin Oncol 1996; 14(3): 796–9

    PubMed  CAS  Google Scholar 

  87. Rohl J, Kushner D, Markman M. Chronic administration of single-agent paclitaxel in gynecologic malignancies. Gynecol Oncol 2001; 81: 201–5

    Article  PubMed  CAS  Google Scholar 

  88. Von Gruenigen VE, Karlen JR, Waggoner SE. A case of chronic paclitaxel administration in ovarian cancer. Gynecol Oncol 2003; 89: 532–5

    Article  Google Scholar 

  89. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21(13): 2460–5

    Article  PubMed  CAS  Google Scholar 

  90. Markman M, Liu P, Wilcyznski S, et al. Survival of ovarian cancer patients treated on SWOG 9701/GOG178: 12 versus 3 cycles of monthly single-agent paclitaxel following attainment of a clinically-defined complete response to platinum/pacli-taxel [abstract no. 5005]. J Clin Oncol 2006; 24 (18S): 257s

    Google Scholar 

  91. Conte PF, Favalli G, Gadducci A, et al. Final results of After-6 protocol 1: a phase III trial of observation versus 6 courses of paclitaxel in advanced ovarian cancer patients in complete response after platinum-paclitaxel chemotherapy [abstract no. 5505]. J Clin Oncol 2007; 25(18S): 275s

    Google Scholar 

  92. Vergote I, De BJ, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001; 357(9251): 176–82

    Article  PubMed  CAS  Google Scholar 

  93. Vergote IB, Kaern J, Abeler VM, et al. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 1993; 169(1): 40–52

    PubMed  CAS  Google Scholar 

  94. Young RC, Brady MF, Nieberg RK, et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin-a Gynecologic Oncology Group study. J Clin Oncol 2003; 21(23): 4350–5

    Article  PubMed  CAS  Google Scholar 

  95. Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate. Ann Oncol 1995; 6: 887–93

    PubMed  CAS  Google Scholar 

  96. Trimbos JB, Vergote I, Bolis G, et al. for the EORTC-ACTION Collaborators. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemo-Therapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003; 95(2): 113–25

    CAS  Google Scholar 

  97. International Collaborative Ovarian Neoplasm (ICON1) Collaborators. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003; 95(2): 125–32

    Article  Google Scholar 

  98. International Collaborative Ovarian Neoplasm 1 (ICON1) and European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant Chemotherapy in Ovarian Neoplasm (EORTC-ACTION). International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95(2): 105–12

    Article  Google Scholar 

  99. Elit L, Chambers A, Fyles A, et al. Systematic review of adjuvant care for women with stage I ovarian carcinoma. Cancer 2004; 101(9): 1926–35

    Article  PubMed  Google Scholar 

  100. Winter-Roach B, Hooper L, Kitchener H. Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer. Int J Gynecol Cancer 2003; 13(4): 395–404

    Article  PubMed  CAS  Google Scholar 

  101. Swart AC. Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON 1) [abstract no. 5509]. J Clin Oncol 2007; 25(18S): 276s

    Google Scholar 

  102. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 102(3): 432–9

    Article  PubMed  CAS  Google Scholar 

  103. Fumoleau P, Kerbrat P, Romestaing P, et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 2003; 21(2): 298–305

    Article  PubMed  CAS  Google Scholar 

  104. McGuire WP, Markman M. Primary ovarian cancer: current standards of care. BJC 2003; 89 Suppl. 3: S3-8

    Google Scholar 

  105. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000; 5(1): 26–35

    Article  PubMed  CAS  Google Scholar 

  106. Gershenson D, Kavanagh JJ, Copeland LJ, et al. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol 1989; 73: 798–802

    PubMed  CAS  Google Scholar 

  107. Gore ME, Fryatt I, Wiltshaw E, et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36(2): 207–11

    Article  PubMed  CAS  Google Scholar 

  108. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9(3): 389–93

    PubMed  CAS  Google Scholar 

  109. Markman M, Kennedy A, Webster K, et al. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. Gynecol Oncol 1997; 65(3): 434–6

    Article  PubMed  CAS  Google Scholar 

  110. Dizon DS, Hensley ML, Poynor EA, et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002; 20(5): 1238–47

    Article  PubMed  CAS  Google Scholar 

  111. Gronlund B, Hogdall C, Hansen HH, et al. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol 2001; 83(1): 128–34

    Article  PubMed  CAS  Google Scholar 

  112. Rose PG, Fusco N, Fluellen L, et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998; 16(4): 1494–7

    PubMed  CAS  Google Scholar 

  113. Hoskins PJ, O’Reilly SE, Swenerton KD. The ‘failure free interval’ defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing. Int J Gynecol Cancer 1991; 1: 205–8

    Article  Google Scholar 

  114. Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004; 22(15): 3120–5

    Article  PubMed  CAS  Google Scholar 

  115. Dizon DS, Dupont J, Anderson S, et al. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel: the Memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 2003; 91(3): 584–90

    Article  PubMed  CAS  Google Scholar 

  116. Markman M, Hoskins W. Responses to ‘salvage’ chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 1992; 10: 513–4

    PubMed  CAS  Google Scholar 

  117. Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999; 17(4): 1141–5

    PubMed  CAS  Google Scholar 

  118. Polyzos A, Tsavaris N, Kosmas C, et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 2001; 61(2): 129–33

    Article  PubMed  CAS  Google Scholar 

  119. Navo M, Kunthur A, Badell ML, et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 2006; 103(2): 608–13

    Article  PubMed  CAS  Google Scholar 

  120. Rose PG, Fusco N, Fluellen L, et al. Carboplatin hypersensitivity reactions in patients with ovarian and peritoneal carcinoma. Int J Gynecol Cancer 1998; 8: 365–8

    Article  Google Scholar 

  121. Schwartz JR, Bandera C, Bradley A, et al. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants’ Hospital. Gynecol Oncol 2007; 105(1): 81–3

    Article  PubMed  CAS  Google Scholar 

  122. Rose PG, Fusco N, Smrekar M, et al. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol 2003; 89(3): 429–33

    Article  PubMed  CAS  Google Scholar 

  123. Jones R, Ryan M, Friedlander M. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecol Oncol 2003; 89(1): 112–5

    Article  PubMed  CAS  Google Scholar 

  124. Robinson JB, Singh D, Bodurka-Bevers DC, et al. Hypersensitivity reactions and the utility of oral and intravenous desensiti-zation in patients with gynecologic malignancies. Gynecol Oncol 2001; 82(3): 550–8

    Article  PubMed  CAS  Google Scholar 

  125. Broome CB, Schiff RI, Friedman HS. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med Pediatr Oncol 1996; 26(2): 105–10

    Article  PubMed  CAS  Google Scholar 

  126. McElroy TM, Gruenigen VE, Waggoner SE. A case of prolonged carboplatin therapy in a patient with carboplatin hypersensitivity. Gynecol Oncol 2003; 91(2): 435–7

    Article  PubMed  Google Scholar 

  127. Markman M, Hsieh F, Zanotti K, et al. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. J Cancer Res Clin Oncol 2004; 130(1): 25–8

    Article  PubMed  CAS  Google Scholar 

  128. Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 1994; 53(1): 121–2

    Article  PubMed  CAS  Google Scholar 

  129. Dizon DS, Sabbatini PJ, Aghajanian C, et al. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002; 84(3): 378–82

    Article  PubMed  CAS  Google Scholar 

  130. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099–106

    Article  CAS  Google Scholar 

  131. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24(29): 4699–707

    Article  PubMed  CAS  Google Scholar 

  132. Vergote I, Himmelmann A, Frankendal B, et al. Hexamethylme-lamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol 1992; 47(3): 282–6

    Article  PubMed  CAS  Google Scholar 

  133. Manetta A, Tewari K, Podczaski ES. Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. Gynecol Oncol 1997; 66(1): 20–6

    Article  PubMed  CAS  Google Scholar 

  134. Markman M, Blessing JA, Moore D, et al. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 1998; 69(3): 226–9

    Article  PubMed  CAS  Google Scholar 

  135. Rustin GJ, Nelstrop AE, Crawford M, et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. J Clin Oncol 1997; 15(1): 172–6

    PubMed  CAS  Google Scholar 

  136. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007; 25(33): 5165–71

    Article  PubMed  CAS  Google Scholar 

  137. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cacner. J Clin Oncol 2007; 25(33): 5180–6

    Article  PubMed  CAS  Google Scholar 

  138. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 2008; 26(1): 76–82

    Article  PubMed  CAS  Google Scholar 

  139. Wright JD, Hagemann A, Rader JS, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006; 107(1): 83–9

    Article  PubMed  CAS  Google Scholar 

  140. Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003; 88(2): 130–5

    Article  PubMed  CAS  Google Scholar 

  141. Verschraegen CF, Sittisomwong T, Kudelka AP, et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 2000; 18(14): 2733–9

    PubMed  CAS  Google Scholar 

  142. Havsteen H, Bertelsen K, Gadeberg CC, et al. A phase 2 study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer. Gynecol Oncol 1996; 63(2): 210–5

    Article  PubMed  CAS  Google Scholar 

  143. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994; 12(1): 60–3

    PubMed  CAS  Google Scholar 

  144. deWit R, van der Burg ME, van den GA, et al. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann Oncol 1994; 5(7): 656–7

    CAS  Google Scholar 

  145. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16(2): 405–10

    PubMed  CAS  Google Scholar 

  146. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxo-rubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007; 25(19): 2811–8

    Article  PubMed  CAS  Google Scholar 

  147. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86(20): 1530–3

    Article  PubMed  CAS  Google Scholar 

  148. D’Agostino G, Amant F, Berteloot P, et al. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 2003; 88(3): 266–9

    Article  PubMed  CAS  Google Scholar 

  149. Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63(1): 89–93

    Article  PubMed  CAS  Google Scholar 

  150. Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992; 10(2): 243–8

    PubMed  CAS  Google Scholar 

  151. Bodurka DC, Levenback C, Wolf JK, et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 2003; 21(2): 291–7

    Article  PubMed  CAS  Google Scholar 

  152. Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18(17): 3093–100

    PubMed  CAS  Google Scholar 

  153. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19(14): 3312–22

    PubMed  CAS  Google Scholar 

  154. Campos SM, Penson RT, Mays AR, et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 2001; 81(2): 206–12

    Article  PubMed  CAS  Google Scholar 

  155. Rose PG, Maxson JH, Fusco N, et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 2001; 82(2): 323–8

    Article  PubMed  CAS  Google Scholar 

  156. Kita T, Kikuchi Y, Takano M, et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol Oncol 2004; 92(3): 813–8

    Article  PubMed  CAS  Google Scholar 

  157. Markman M, Blessing J, Rubin SC, et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 101(3): 436–40

    Article  PubMed  CAS  Google Scholar 

  158. Markman M, Iseminger KA, Hatch KD, et al. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol Oncol 1996; 62(1): 4–6

    Article  PubMed  CAS  Google Scholar 

  159. Ahlgren JD, Ellison NM, Gottlieb RJ, et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993; 11(10): 1957–68

    PubMed  CAS  Google Scholar 

  160. Williams CJ. Tamoxifen in relapsed ovarian cancer: a systematic review. Int J Gynecol Cancer 1998; 8: 89–94

    Article  Google Scholar 

  161. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14: 3056–61

    PubMed  CAS  Google Scholar 

  162. ten Bokkel HW, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15(6): 2183–93

    Google Scholar 

  163. Spannuth WA, Leath III CA, Huh WK, et al. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. Gynecol Oncol 2007; 104(3): 591–5

    Article  PubMed  CAS  Google Scholar 

  164. Gershenson DM, Burke TW, Morris M, et al. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol 1998; 70(3): 404–9

    Article  PubMed  CAS  Google Scholar 

  165. Bajetta E, Di LA, Biganzoli L, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1996; 14(9): 2546–51

    PubMed  CAS  Google Scholar 

  166. Vergote I, Finkler N, del Campo J, et al. Single agent, canfos-famide versus pegylated doxorubicin or topotecan in 3rd line treatment of platinum refractory or resistant ovarian cancer: phase 3 study results [abstract no. LBA55289]. J Clin Oncol 2007; 25 (18S Pt II): 966s

    Google Scholar 

  167. Markman M, Webster K, Zanotti K, et al. Survival following the documentation of platinum and taxane-resistance in ovarian cancer: a single institution experience involving multiple phase 2 trials. Gynecol Oncol 2004; 93: 699–701

    Article  PubMed  CAS  Google Scholar 

  168. Markman M. Viewing ovarian cancer as a ‘chronic disease’: what exactly does this mean? Gynecol Oncol 2006; 100(2): 229–30

    Article  PubMed  Google Scholar 

  169. Markman M. Why study third-, fourth-, fifth-… line chemotherapy of ovarian cancer? Gynecol Oncol 2001; 83(3): 449–50

    Article  PubMed  CAS  Google Scholar 

  170. Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21(2): 283–90

    Article  PubMed  CAS  Google Scholar 

  171. Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 2005; 11(15): 5539–48

    Article  PubMed  CAS  Google Scholar 

  172. Sciden MV, Burris HA, Matulonis U, et al. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 2007; 104(3): 727–31

    Article  CAS  Google Scholar 

  173. Posadas EM, Liel MS, Kwitkowski V, et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007; 109(7): 1323–30

    Article  PubMed  CAS  Google Scholar 

  174. Coleman RL, Broaddus RR, Bodurka DC, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum-and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 2006; 101(1): 126–31

    Article  PubMed  CAS  Google Scholar 

  175. Alberts DS, Liu PY, Wilczynski SP, et al. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Cancer 2007; 17: 784–8

    Article  PubMed  CAS  Google Scholar 

  176. Posadas EM, Kwitkowski V, Kotz HL, et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 2007; 110: 309–17

    Article  PubMed  CAS  Google Scholar 

  177. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50(13): 4087–91

    PubMed  CAS  Google Scholar 

  178. Felip E, del Campo JM, Rubio D, et al. Overexpression of cerbB-2 in epithelial ovarian cancer: prognostic value and relationship with response to chemotherapy. Cancer 1995; 75(8): 2147–52

    Article  PubMed  CAS  Google Scholar 

  179. Meden H, Marx D, Roegglen T, et al. Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int J Gynecol Pathol 1998; 17(1): 61–5

    Article  PubMed  CAS  Google Scholar 

  180. Tew WP, Colombo N, Ray-Coquard I, et al. VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer: preliminary results of a randomized multi-center phase II study [abstract]. J Clin Oncol 2007; 25(18S): 276s

    Google Scholar 

  181. Malkasian Jr GD, Decker DG, Jorgensen EO, et al. 6-Dehydro-6,17 alpha-dimethylprogesterone (NSC-123018) for the treatment of metastatic and recurrent ovarian carcinoma. Cancer Chemother Rep 1973; 57(2): 241–2

    PubMed  Google Scholar 

  182. Ward HW. Progestogen therapy for ovarian carcinoma. J Obstet Gynaecol Br Commonw 1972; 79(6): 555–9

    Article  PubMed  CAS  Google Scholar 

  183. Makar AP. Hormone therapy in epithelial ovarian cancer. Endocr Relat Cancer 2000; 7(2): 85–93

    Article  PubMed  CAS  Google Scholar 

  184. Schwartz PE, Chambers JT, Kohorn EI, et al. Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer: a prospective randomized trial. Cancer 1989; 63(6): 1074–8

    Article  PubMed  CAS  Google Scholar 

  185. Perez-Gracia JL, Carrasco EM. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol 2002; 84(2): 201–9

    Article  PubMed  CAS  Google Scholar 

  186. Markman M, Webster K, Zanotti K, et al. Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecol Oncol 2004; 93(2): 390–3

    Article  PubMed  CAS  Google Scholar 

  187. Ercoli A, Scambia G, De VR, et al. Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: enhancement of DNA platination as a possible mechanism. Cancer Lett 1996; 108(1): 7–14

    Article  PubMed  CAS  Google Scholar 

  188. McClay EF, Albright KD, Jones JA, et al. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br J Cancer 1994; 70(3): 449–52

    Article  PubMed  CAS  Google Scholar 

  189. Geisinger KR, Berens ME, Duckett Y, et al. The effects of estrogen, progesterone, and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro. Cancer 1990; 65(5): 1055–61

    Article  PubMed  CAS  Google Scholar 

  190. Benedetti PP, Greggi S, Amoroso M, et al. A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a phase II study. Int J Gynecol Cancer 2001; 11(6): 438–44

    Article  Google Scholar 

  191. Markman M, Webster K, Zanotti K, et al. Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum. Gynecol Oncol 2004; 94(2): 404–8

    Article  PubMed  CAS  Google Scholar 

  192. Kavanagh JJ, Roberts W, Townsend P, et al. Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol 1989; 7(1): 115–8

    PubMed  CAS  Google Scholar 

  193. Sikic BI, Scudder SA, Ballon SC, et al. High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group. Semin Oncol 1986; 13 (4 Suppl. 4): 26–32

    PubMed  CAS  Google Scholar 

  194. Bowman A, Gabra H, Langdon SP, et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 2002; 8(7): 2233–9

    PubMed  CAS  Google Scholar 

  195. Gourley C, Smyth JF, Mackean M, et al. Phase III study of letrozole in estrogen receptor positive relapsed epithelial ovarian cancer [abstract no. 5025]. J Clin Oncol 2006; 24(18S): 261s

    Google Scholar 

  196. Fruehauf JP. In vitro assay-assisted treatment selection for women with breast or ovarian cancer. Endocr Relat Cancer 2002; 9(3): 171–82

    Article  PubMed  CAS  Google Scholar 

  197. Von Hoff DD, Kronmal R, Salmon SE, et al. A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer 1991; 67(1): 20–7

    Article  Google Scholar 

  198. Nagourney RA, Brewer CA, Radecki S, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 2003; 88(1): 35–9

    Article  PubMed  CAS  Google Scholar 

  199. Holloway RW, Mehta RS, Finkler NJ, et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 2002; 87(1): 8–16

    Article  PubMed  CAS  Google Scholar 

  200. Sharma S, Neale MH, Di NF, et al. Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 2003; 3: 19–28

    Article  PubMed  Google Scholar 

  201. Khoo SK, Hurst T, Webb MJ, et al. Measurement of tumor cell activity in short-term primary culture: clinical significance in women with ovarian cancer. Cancer 1988; 61(8): 1579–86

    Article  PubMed  CAS  Google Scholar 

  202. Gallion H, Christopherson WA, Coleman RL, et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 2006; 16(1): 194–201

    Article  PubMed  CAS  Google Scholar 

  203. Samson DJ, Scidenfeld J, Ziegler K, et al. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 2004; 22(17): 3618–30

    Article  PubMed  CAS  Google Scholar 

  204. Schrag D, Garewal HS, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 2004; 22(17): 3631–8

    Article  PubMed  CAS  Google Scholar 

  205. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975; 42: 101–4

    PubMed  CAS  Google Scholar 

  206. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000; 78 (3 Pt 1): 269–74

    Article  PubMed  CAS  Google Scholar 

  207. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20(5): 1248–59

    Article  PubMed  Google Scholar 

  208. Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992; 47(2): 159–66

    Article  PubMed  CAS  Google Scholar 

  209. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170(4): 974–9

    PubMed  CAS  Google Scholar 

  210. Surwit E, Childers J, Atlas I, et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 1996; 6: 356–61

    Article  Google Scholar 

  211. Lu FK, Kose MF, Boran N, et al. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001; 11: 466–70

    Article  Google Scholar 

  212. Vergote I, DE WI, Tjalma W, et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998; 71(3): 431–6

    Article  PubMed  CAS  Google Scholar 

  213. Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999; 72(1): 93–9

    Article  PubMed  CAS  Google Scholar 

  214. Ansquer Y, Leblanc E, Clough K, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 2001; 91(12): 2329–34

    Article  PubMed  CAS  Google Scholar 

  215. Kuhn W, Rutke S, Spathe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 2001; 92(10): 2585–91

    Article  PubMed  CAS  Google Scholar 

  216. Chan YM, Ng TY, Ngan HY, et al. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 2003; 88(1): 9–16

    Article  PubMed  CAS  Google Scholar 

  217. Hou JY, Kelly MG, Yu H, et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 2007; 105(1): 211–7

    Article  PubMed  CAS  Google Scholar 

  218. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006; 103(3): 1070–6

    Article  PubMed  CAS  Google Scholar 

  219. Rustin GJ, Marples M, Nelstrop AE, et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001; 19(20): 4054–7

    PubMed  CAS  Google Scholar 

  220. Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14(5): 1545–51

    PubMed  CAS  Google Scholar 

  221. Rustin GJ, Nelstrop AE, Bentzen SM, et al. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 2000; 18(8): 1733–9

    PubMed  CAS  Google Scholar 

  222. Bridgewater JA, Nelstrop AE, Rustin GJ, et al. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 1999; 17(2): 501–8

    PubMed  CAS  Google Scholar 

  223. Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996; 7(4): 361–4

    Article  PubMed  CAS  Google Scholar 

  224. Gronlund B, Hogdall C, Hilden J, et al. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 2004; 22(20): 4051–8

    Article  PubMed  Google Scholar 

  225. Vergote I, Rustin GJ, Eisenhauer EA, et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). Gynecologic Cancer Intergroup. J Natl Cancer Inst 2000; 92(18): 1534–5

    CAS  Google Scholar 

  226. Markman M. The myth of measurable disease in ovarian cancer. J Clin Oncol 2003; 21(16): 3013–5

    Article  PubMed  Google Scholar 

  227. Markman M. Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials. Gynecol Oncol 2007; 106: 279–81

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The author has received honoraria from Genentech, Eli Lilly and Tibutech.

Author information

Authors and Affiliations

  1. Department of Gynecologic Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA

    Maurie Markman

Authors
  1. Maurie Markman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurie Markman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markman, M. Pharmaceutical Management of Ovarian Cancer. Drugs 68, 771–789 (2008). https://doi.org/10.2165/00003495-200868060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200868060-00004

Keywords

Search

Navigation